Help improve the information
Suggest a correction, missing detail, or peptide addition by .
Not FDA approved
This peptide is not FDA approved for human use, and because peptides are often incompletely studied you should not use or self-experiment with it outside qualified medical supervision.
Overview
BPC-157 is an experimental 15-amino-acid peptide based on a gastric body-protection compound. The reviewed source set supports broad preclinical literature across gastrointestinal, tendon, muscle, nerve, and vascular injury models, plus only very limited human evidence: a registered oral phase I study with no posted results identified and a 2025 two-person intravenous tolerability pilot.
That is not enough to present BPC-157 as an established therapy or a validated self-use protocol.
Reported benefits
- Strong preclinical interest in gastrointestinal cytoprotection and connective-tissue healing.
- Broad animal-model coverage across tendon, muscle, nerve, vascular, and GI injury settings.
- Human evidence remains too limited for broad efficacy or long-term safety claims.
- No FDA-approved product or labeled therapeutic use was identified.
Mechanism of action
The recurring mechanistic themes in the primary literature are angiogenesis (new blood vessel growth)-related signaling, nitric-oxide modulation, cell protection, fibroblast (a repair cell that builds connective tissue) migration, and pathway changes associated with tendon or ligament healing. Those findings explain why BPC-157 keeps appearing in injury-model papers, but they do not prove clinical efficacy, guaranteed oral bioavailability (how much of it reaches circulation and tissues), or a validated human protocol.
Reported Use
No FDA dosing guidance
This peptide is not covered by FDA-labeled dosing guidance on this page. Peptides are often investigational or incompletely studied. Do not self-experiment; use only with a doctor or qualified clinician.
Typical dose
No validated general-use dose established; the reviewed human literature is too limited to support routine self-use dosing
Frequency
Not established
Injection sites
Published human evidence does not support a generalized self-injection rule
Best timing
Not established
Effects timeline
Not established for routine use
Storage
Do not treat generic vial-handling instructions as validated medical guidance
Cycle length
Not established
Break between
Not established
Sequence
GEPPPGKPADDAGLV
Loading viewer
Preparing 3D peptide scene
Quick Signals
At A Glance
A faster read on evidence, focus, structure, and status.
Evidence
Mostly preclinical
Extensive preclinical evidence with very limited human evidence.
209 indexed studiesCurrent level
Preclinical
Scale: low evidence to established use
Safety
Side Effects And Safety
Switch between common side-effect notes and stop criteria to keep safety context visible.
Reported or plausible side effects
- Practical risks include injection-site irritation and product-quality or sterility problems outside regulated manufacturing.
Key cautions
- No FDA-labeled safety profile exists for BPC-157.
- Published human safety data are too limited to call the overall risk profile well established.
- Pregnancy and breastfeeding safety are not established.
Molecule
Molecular Information
Core structure fields that help explain what kind of peptide this is and how much sequence detail is available.
Molecular weight
1,419.53 Da
Chain length
15 amino acids (pentadecapeptide)
Sequence type
Linear synthetic peptide
Derived from
Partial sequence of a gastric body-protection compound
Amino acid sequence source string
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Synthetic pentadecapeptide modeled on a gastric-juice peptide fragment
Context
Important Context
The main context that changes how confidently this peptide should be interpreted.
Research status
Extensive preclinical evidence with very limited human evidence. The strongest reviewed human anchors are a registered oral phase I study with no posted results identified and a two-person IV tolerability pilot.
Regulatory and sport status
FDA review shows it is not FDA approved. based on an openFDA no-match query plus FDA peptide safety context. Sport review: WADA treats BPC-157 as prohibited under S0.
Use extra caution if
- • Pregnancy or breastfeeding because no approved therapeutic framework or adequate safety data were identified.
- • Competitive athletics because anti-doping authorities treat BPC-157 as prohibited.
Blend composition
Single compoundSingle active ingredient: BPC-157.
Route Notes
Route-Specific Notes
Only shown when the source material adds route-specific details beyond the quick-start guide.
Injectable
- Administration: Published human evidence does not support a generalized self-injection rule.
- Absorption: Reliable human absorption guidance was not established in the reviewed source set.
- Cycle: Not established
- Additional: The 2025 IV pilot addressed short-term tolerability only and does not create a consumer-use protocol.
Oral
- Administration: A registered oral phase I study exists, but no validated self-use protocol was identified.
- Absorption: Claims of reliable oral human bioavailability should be treated cautiously.
- Cycle: Not established
- Additional: Trial registration alone is not the same as an established therapeutic program.
Compare
How Well Documented Is It?
A quick five-point snapshot of how visible and well-documented this peptide is. Higher values mean more coverage or clearer status in that area, not better medical performance.
Research
How much published research coverage this peptide has in the linked sources, with an approval-context floor for clearly established drug products.
Source: PubMed
Regulatory
How clearly the approval or regulatory status is documented for this entry.
Source: openFDA drugsfda API
Sport
How clearly sports or competition status is documented in the linked review sources.
Source: 2026 WADA Prohibited List PDF
Breadth
How broadly this peptide appears across discussion topics and use-case groupings in the catalog.
Source: Curated site taxonomy
Sequence
How much structure or residue-sequence detail is available for this entry.
Source: Sequence
Protocols
Research Protocols
Common protocol-style rows shown in a consistent table layout so every peptide page is easy to compare.
| Goal | Dose | Route | Frequency |
|---|---|---|---|
| Registered oral phase I safety / pharmacokinetic study | Study-specific | Oral | Fixed trial schedule |
| 2025 pilot IV safety study | 10 mg then 20 mg | IV infusion | Study-specific |
| Preclinical tendon, gut, and tissue-repair models | Model-specific | Animal-study-specific | Protocol-specific |
Research
What It Has Been Studied For
Plain-language summaries of the main health areas where this peptide shows up in the linked research.
Stacking
What People Commonly Stack It With
A plain-language view of compounds that are commonly discussed alongside this peptide in the source material.
Practical
Preparation, Quality, And Expectations
Operational checklist blocks designed for quick scanning and repeatable page structure.
How to reconstitute
- •No validated consumer reconstitution protocol was identified for exact BPC-157.
- •Do not treat generic BAC-water instructions as verified medical guidance.
- •If identity, sterility, or stability is unclear, do not use the product.
Quality indicators
Good signs
- Exact identity, concentration, and batch documentation are available.
- Source material clearly separates preclinical findings from limited human evidence.
Avoid
- Unverifiable identity, concentration, or sterility claims.
- Marketing that presents animal findings as proven human outcomes.
- Cloudiness, discoloration, or visible particles.
- Pages that sell a precise healing, stacking, or reconstitution protocol as if it were source-backed.
What to expect
Many repair and ulcer-healing outcomes were measured over days to weeks in preclinical work.
The small human studies do not establish a reliable symptom-improvement timeline.
No validated consumer expectation curve was identified.
References
Research And Source List
Structured reference cards with source metadata and a direct link so users can inspect the original study/source.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide
Pharmaceuticals | 2025
Recent review covering the broad preclinical literature and the still-limited human evidence picture.
Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157
Frontiers in Pharmacology | 2022
Preclinical pharmacokinetic paper; useful for animal PK context, not a human dosing template.
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
Frontiers in Pharmacology | 2021
Mechanistic and wound-healing review focused largely on preclinical work.
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Alternative Therapies in Health and Medicine | 2025
Two-person IV pilot reporting short-term tolerability only; not proof of efficacy or broad safety.
ClinicalTrials.gov NCT02637284
Registered oral phase I study
Registered oral phase I safety / pharmacokinetic study in healthy volunteers; posted results were not identified in the reviewed source set.
openFDA BPC-157 query
FDA database
Approval-database query reviewed for BPC-157; no FDA-approved product match was identified.
FDA peptide safety page
FDA
FDA safety and regulatory context for peptide products marketed for human use.
2026 WADA Prohibited List PDF
WADA
Current anti-doping source used for prohibited-in-sport review.
PubChem compound record
Technical identity
Compound registry record supporting the molecular identity fields used on this page.
Catalog profile
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. It's known for its remarkable healing properties and is extensively researched for tissue repair, inflammation reduction, and gastrointestinal protection. Not FDA approved and prohibited by WADA (added 2022) under S0: Non-Approved Substances - no TUE available for athletes.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide
Comprehensive review of BPC 157's biological activities, mechanisms of action, and therapeutic potential across multiple organ systems including wound healing, neuroprotection, and gastrointestinal protection.